SRS Medical

Executive Summary

SRS Medical is a U.S.-based medical device and diagnostics company dedicated to improving the management of male lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Founded in 1990 and headquartered in Bellevue, Washington, the company offers a comprehensive suite of integrated diagnostic tools and clinical decision support software designed to guide urologists in making data-driven treatment decisions. By emphasizing the preservation of bladder function, SRS Medical aims to standardize care pathways and optimize the timing of interventions, ultimately improving patient outcomes. The company's solutions address a significant unmet need in urology, where treatment decisions have historically been subjective and variable across practices. As a private company with a long operating history, SRS Medical has established a foothold in the urology diagnostics market. However, limited public information is available regarding its financial performance, recent funding, or clinical evidence. The company's focus on evidence-based, standardized care aligns with broader healthcare trends toward value-based medicine and personalized treatment. Given its niche focus and established presence, SRS Medical is well-positioned to capture market share, but growth may hinge on product innovation and adoption by urology practices. Overall, the company represents a moderate opportunity within the medical devices sector, with potential upside from new product launches and expanding clinical validation.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Next-Generation Diagnostic Platform70% success
• Q2 2026Publication of Real-World Evidence Study in Peer-Reviewed Journal80% success
• H2 2026Strategic Partnership with Large Urology Practice Group60% success